JP Morgan Chase’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.95M Buy
145,157
+114,502
+374% +$1.83M ﹤0.01% 4126
2025
Q4
$236K Sell
30,655
-1,577
-5% -$12.4K ﹤0.01% 5450
2025
Q3
$238K Buy
32,232
+1,812
+6% +$9.27K ﹤0.01% 5426
2025
Q2
$122K Buy
30,420
+25,681
+542% +$93.4K ﹤0.01% 5516
2025
Q1
$15.1K Sell
4,739
-19,716
-81% -$92.9K ﹤0.01% 6220
2024
Q4
$131K Sell
24,455
-25,101
-51% -$187K ﹤0.01% 5649
2024
Q3
$262K Buy
49,556
+40,404
+441% +$145K ﹤0.01% 5284
2024
Q2
$16.7K Sell
9,152
-43,672
-83% -$81.4K ﹤0.01% 6178
2024
Q1
$94K Buy
52,824
+52,145
+7,680% +$109K ﹤0.01% 5700
2023
Q4
$1.2K Sell
679
-69,228
-99% -$101K ﹤0.01% 6808
2023
Q3
$102K Buy
69,907
+68,706
+5,721% +$145K ﹤0.01% 5459
2023
Q2
$2.75K Hold
1,201
﹤0.01% 6288
2023
Q1
$1K Hold
1,201
﹤0.01% 6507
2022
Q4
$1K Sell
1,201
-1,585
-57% -$1.4K ﹤0.01% 6390
2022
Q3
$2K Buy
2,786
+818
+42% +$780 ﹤0.01% 6236
2022
Q2
$2K Sell
1,968
-3,531
-64% -$4.33K ﹤0.01% 6275
2022
Q1
$9K Buy
5,499
+1,396
+34% +$2.56K ﹤0.01% 6222
2021
Q4
$10K Buy
+4,103
New +$15.9K ﹤0.01% 6333
2019
Q3
Sell
-66,687
Closed -$226K 5752
2019
Q2
$226K Sell
66,687
-100,434
-60% -$393K ﹤0.01% 4617
2019
Q1
$673K Sell
167,121
-62,171
-27% -$262K ﹤0.01% 4039
2018
Q4
$841K Buy
229,292
+111,779
+95% +$762K ﹤0.01% 3857
2018
Q3
$1.01M Buy
117,513
+2,997
+3% +$30K ﹤0.01% 3913
2018
Q2
$1.26M Sell
114,516
-103,681
-48% -$1.16M ﹤0.01% 3696
2018
Q1
$2.52M Sell
218,197
-27,264
-11% -$258K ﹤0.01% 3101
2017
Q4
$2.54M Sell
245,461
-70,739
-22% -$906K ﹤0.01% 3171
2017
Q3
$5.11M Sell
316,200
-16,434
-5% -$227K ﹤0.01% 2558
2017
Q2
$4.03M Buy
332,634
+178,658
+116% +$1.91M ﹤0.01% 2615
2017
Q1
$3.2M Sell
153,976
-26,123
-15% -$409K ﹤0.01% 2734
2016
Q4
$2.58M Buy
180,099
+15,199
+9% +$231K ﹤0.01% 2904
2016
Q3
$2.71M Sell
164,900
-10,200
-6% -$147K ﹤0.01% 2618
2016
Q2
$2.5M Buy
+175,100
New +$2.37M ﹤0.01% 2692

Other funds holding CRVS